Literature DB >> 24390402

Intravitreal injection of (99)Tc-MDP inhibits the development of laser-induced choroidal neovascularization in rhesus monkeys.

Kunbei Lai1, Chenjin Jin, Shu Tu, Yunfan Xiong, Rui Huang, Jian Ge.   

Abstract

BACKGROUND: The aim of this study was to investigate the safety and efficacy of intravitreal injection of (99)Tc-MDP, a decay product of (99m)Tc-MDP, on the development of laser-induced choroidal neovascularization (CNV) in rhesus monkeys.
METHODS: Experimental CNV was induced by argon laser with a small high-energy laser spot. Monkeys were given 50 μL of (99)Tc-MDP at a concentration of 0.005 μg/mL (n = 6) or 0.01 μg/mL (n = 6) by intravitreal injection once a week immediately after laser injury for a period of 56 days. Control animals were treated with the same volume of PBS (n = 6) in the same way. Eyes were monitored by ophthalmic examination, color fundus photography, fluorescence fundus angiography (FFA), optical coherence tomography (OCT) and histology. Incidences of grade 4 CNV lesions as well as the leakage areas of grade 4 CNVs on the late-phase of fluorescein angiograms were measured in a standardized, randomized and masked fashion fortnightly. The maximum widths and heights of grade 4 CNVs were also calculated by histology at the end of the experiment. Toxicity of (99)Tc-MDP on the retina was evaluated by electroretinogram (ERG) and histologic analysis.
RESULTS: (99)Tc-MDP reduced the incidences of grade 4 CNVs by 33.33 % and 39.40 % in the 0.005 μg/mL and 0.01 μg/mL groups, respectively, compared with the PBS group on day 28 (P < 0.05; n = 6). The leakage areas of grade 4 CNVs were smaller in the 0.005 μg/mL (0.7136 ± 0.0283 mm(2), p <0.01; n = 6) and 0.01 μg/mL (0.4351 ± 0.0349 mm(2), p < 0.01; n = 6) groups than those in the PBS control group (0.9373 ± 0.0455 mm(2); n = 6) in a dose-dependent manner on day 28. OCT and histology also showed that the sizes of CNVs were smaller in the (99)Tc-MDP treated groups than those in the PBS group. Although intravitreal injection of (99)Tc-MDP led to mild inflammatory reaction in the anterior chamber, histology and ERG findings demonstrated that (99)Tc-MDP did not cause any change in histological structure or function of the retina (p>0.05).
CONCLUSIONS: Intravitreal injection of (99)Tc-MDP can inhibit the development of laser-induced CNV without toxic effect on retina, suggesting that (99)Tc-MDP has therapeutic potential for CNV related diseases.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24390402     DOI: 10.1007/s00417-013-2559-1

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  38 in total

1.  Ultrastructure of Bruch's membrane after krypton laser photocoagulation. II. Repair of Bruch's membrane and the role of macrophages.

Authors:  A Pollack; G E Korte; W J Heriot; P Henkind
Journal:  Arch Ophthalmol       Date:  1986-09

2.  Pathologic features of surgically excised subretinal neovascular membranes in age-related macular degeneration.

Authors:  P F Lopez; H E Grossniklaus; H M Lambert; T M Aaberg; A Capone; P Sternberg; N L'Hernault
Journal:  Am J Ophthalmol       Date:  1991-12-15       Impact factor: 5.258

Review 3.  Current concepts in the pathogenesis of age-related macular degeneration.

Authors:  Marco A Zarbin
Journal:  Arch Ophthalmol       Date:  2004-04

Review 4.  A role for local inflammation in the formation of drusen in the aging eye.

Authors:  Don H Anderson; Robert F Mullins; Gregory S Hageman; Lincoln V Johnson
Journal:  Am J Ophthalmol       Date:  2002-09       Impact factor: 5.258

5.  Macrophage depletion inhibits experimental choroidal neovascularization.

Authors:  Eiji Sakurai; Akshay Anand; Balamurali K Ambati; Nico van Rooijen; Jayakrishna Ambati
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-08       Impact factor: 4.799

6.  Targeted disruption of the CD18 or ICAM-1 gene inhibits choroidal neovascularization.

Authors:  Eiji Sakurai; Hogara Taguchi; Akshay Anand; Balamurali K Ambati; Evangelos S Gragoudas; Joan W Miller; Anthony P Adamis; Jayakrishna Ambati
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-06       Impact factor: 4.799

7.  Retinal safety of a new fluoroquinolone, pradofloxacin, in cats: assessment with electroretinography.

Authors:  Andre Messias; Florian Gekeler; Alfred Wegener; Klaus Dietz; Konrad Kohler; Eberhart Zrenner
Journal:  Doc Ophthalmol       Date:  2007-10-02       Impact factor: 2.379

8.  Liposomal benzoporphyrin derivative verteporfin photodynamic therapy. Selective treatment of choroidal neovascularization in monkeys.

Authors:  M Kramer; J W Miller; N Michaud; R S Moulton; T Hasan; T J Flotte; E S Gragoudas
Journal:  Ophthalmology       Date:  1996-03       Impact factor: 12.079

9.  Effects of Yunke (technetium-99 conjugated with methylene diphosphonate; (99)Tc-MDP) and/or colloidal chromic phosphate phosphonium-32, alone and in combination, in rats with adjuvant arthritis.

Authors:  Liming Wang; Qiangrong Gu; Yan Xu; Shaohua Li; Jianchao Gui; Jianping Yang; Qingqiang Yao; Yong Ji
Journal:  Clin Exp Pharmacol Physiol       Date:  2008-01       Impact factor: 2.557

10.  Rationale for combination therapy in age-related macular degeneration.

Authors:  Richard F Spaide
Journal:  Retina       Date:  2009-06       Impact factor: 4.256

View more
  3 in total

1.  Multimodal imaging of the retina and choroid in healthy Macaca fascicularis at different ages.

Authors:  Shuxin Fan; Xiaoyan Ding; Pinhong Rao; Yingfeng Zheng; Fuxiang Mao; Youjin Hu; Xialin Liu; Guoping Fan
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-01-25       Impact factor: 3.117

2.  99Tc-MDP-induced human osteoblast proliferation, differentiation and expression of osteoprotegerin.

Authors:  Jie Chen; Youyu Lan; Yue He; Chengsong He; Fen Xu; Yugao Zhang; Yi Zhao; Yi Liu
Journal:  Mol Med Rep       Date:  2017-06-22       Impact factor: 2.952

3.  Comparing The Efficacy Of An Anti-Human VEGF-A Neutralizing Antibody Versus Bevacizumab On A Laser-Induced Choroidal Neovascularization (CNV) Rhesus Monkey Model.

Authors:  Oscar Olvera-Montaño; Leopoldo Baiza-Duran; Juan D Quintana-Hau; Mayra G Quiñonez-Alvarado; Wen Zeng; Li Gong; Patricia Muñoz-Villegas
Journal:  Drug Des Devel Ther       Date:  2019-11-04       Impact factor: 4.162

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.